• To determine if AMD3100 given after chemo mobilization and G-CSF is generally safe and well tolerated.
  

• To determine if MM and NHL patients mobilized with chemotherapy and G-CSF plus AMD3100 exhibit ≥ 2-fold increase in circulating CD34+ cells.(This will increase the yield during apheresis.)
  
• To determine if MM and NHL patients who are mobilized with G-CSF plus AMD3100 and transplanted with the apheresed cells achieve PMN engraftment by study day 12, but no later than study day 21.
  

This is an open label, multi-center, Phase 2 study. Patients with MM or NHL who are to be treated with PBSC autologous transplantation are eligible for this protocol. The only change to the standard of care is the addition of AMD3100 to a mobilization regimen of chemotherapy and G-CSF. Patients will first be given a mobilizing regimen of chemotherapy as per local practice guidelines and G-CSF (at customary doses) and apheresis will be performed. After the first apheresis, AMD3100 will be given at 10PM, 10 hours before the second apheresis the next day or in the morning of the second day, 6 hours before the second apheresis. The change in the patient's peripheral CD34+ cell count between the AMD3100 dose and the start of apheresis will be measured. The apheresis yields on day one and day two will be compared.